Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for a comparison against the company's own recent past, already real and recurring, and early stage. In the transcript, management discusses various aspects: revenue growth, market share, product launches, international shipments, capacity expansion. They talk about international shipments: "in Q3, we made $1.3 million worth of shipments to Cannatrek and Medcan in Australia. Subsequent to quarter end, we made another shipment to Cannatrek worth $1.8 million. And this month, we made a shipment to Canndoc in Israel worth $3.3 million." That shows increasing shipment values, but are these successive engagements of the same kind? They are shipments to different customers or same? Cannatrek and Medcan are different. The shipment to Cannatrek was $1.3M, then another to Cannatrek $1.8M, then to Canndoc $3.3M. That could indicate larger shipments over time. But is that a pattern? They also say "We expect to make further international shipments in fiscal 2022 and are working on potential opportunities to expand supply arrangements into Europe." So they are expecting more. But is the size of each shipment escalating? Possibly, but it's not clearly stated as a trend. They also mention that they had less international volume than expected due to timing, but they shipped later. Another point: they talk about capacity expansion and filling distribution gaps. They mention that they are expanding distribution of SHRED to more provinces. That is more distribution, not necessarily larger individual deals. They talk about the 4C expansion increasing capacity from 45,000 to 82,000 kg. That is capacity, not deal size. They talk about the acquisition of Laurentian and expanding its capacity. That is internal. They talk about the Centre of Excellence and product development. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.